PHAR Pharming Group

$PHAR (L) Under the radar growth story in the rare disease space Encouraging rebound in Ruconest revenues, despite oral HAE competitors $BCRX $KALV $PHVS Joenja sales +58%, accelerating 2027-2028 via international launch +label expansion to younger patients (notes in Chat) *Caveat, very low trading volume

$PHAR Pharming presenteert positieve studieresultaten met leniolisib tijdens congres Gepubliceerd op 14-10-2026 om 08:11 ABMFN PHARMING GROUP N.V. -3,43% Pharming presenteert positieve studieresultaten met leniolisib tijdens congres (ABM FN-Dow Jones) Pharming Group presenteert vandaag tijdens het ESID 2026 positieve topline resultaten van zijn Fase II-studie met leniolisib bij genetisch identificeerbare primaire immuundeficiënties met immuundisregulatie gerelateerd aan verstoorde PI3K?-signaaloverdracht. Dit maakte het biotechbedrijf woensdagochtend bekend.

$PHAR Pharming Group reports third quarter 2026 financial results; strong revenue growth, Joenja APDS expansion and CVID topline data in November Third quarter 2026 total revenues increased by 21% to US$117.6 million, compared to third quarter 2025, exceeding market expectations RUCONEST® revenue increased by 14% to US$93.8 million, compared to third quarter 2025, reflecting demand stabilization and seasonal inventory increase Joenja® (leniolisib) revenue increased by 58% to US$23.8 million, compared to third quarter 2025, reflecting strong U.S. and international demand Tightened 2026 total revenue guidance to US$380 million - US$390 million from prior US$375 million - US$395 million Operating profit increased by 89% to US$29.9 million, compared to third quarter 2025 Generated US$32.4 million in cash flow from operations in the quarter and US$24.7 million year to date, increasing cash position to US$190.9 million

$PHAR Persoonlijke opmerkingen genoeg, maar hoe zit het eigenlijk met je eigen kennis van Pharming? Wat verwacht jij concreet van RUCONEST nu de omzet is gedaald en de patiëntbasis 7% kleiner is geworden? Ik ben wel eens benieuwd naar jouw eigen inschattingsvermogen. Schelden kan altijd nog.

no PDUFA landing today and honestly that is fine. the next 7 days do the heavy lifting Oct 24 $PHAR Joenja PDUFA, ages 4 to 11 in activated PI3K delta syndrome Oct 24 $MRNA full Phase 3 intismeran melanoma data at ESMO, Presidential Symposium Oct 26 $GSK bepirovirsen PDUFA in chronic hepatitis B everybody spent Friday pricing doom. this week has actual dates to trade around

$PHAR Reported today: EPS of $0.30 vs. $0.15 expected (+100.0%, beat). Revenue of $118M vs. $118M expected (0.0%, in line). I used Stock Meadow’s earnings dashboard to review the results.

$PHAR – Questions Pharming needs to answer Why has RUCONEST’s active patient base gone from 93% of prior-year levels in Q2 to the much vaguer “over 90%” in Q3? Is retention continuing to deteriorate, and what is the actual percentage? Why does management repeatedly emphasize that new prophylactic treatments have not affected RUCONEST demand, while failing to quantify the impact of direct competition from acute treatments such as EKTERLY? RUCONEST competes in the acute HAE market, not the prophylaxis market. Highlighting the absence of an impact from preventive therapies while avoiding hard numbers on direct competitors raises serious questions about transparency. Is Pharming providing investors with the full picture, or selectively presenting information to make RUCONEST’s competitive position look stronger than it actually is? Shareholders deserve clear patient retention, enrollment and discontinuation figures, not carefully worded reassurances.

$PHAR Strong progress on Joenja expansion including U.S. pediatric label and launches in Germany and Japan Announced positive Phase II topline data for leniolisib in genetic PIDs with immune dysregulation and Phase II topline data in broader CVID patient population expected in November 2026 Pharming to host a conference call today at 13:30 CET (8:30 am EDT) Leiden, the Netherlands, October 27, 2026

$PHAR At ESID 2026, Pharming presented positive Phase II data for leniolisib in genetically defined primary immunodeficiencies (PIDs) with immune dysregulation linked to altered PI3Kδ signaling. Leniolisib was generally well-tolerated, with improvements observed in lymphoproliferation and encouraging trends in lung and liver disease markers. All 12 participants who completed the study elected to continue receiving leniolisib in a long-term extension study. These results represent the first clinical data for leniolisib in a larger group of PID participants beyond APDS, supporting the potential of targeted PI3Kδ inhibition to address immune dysregulation. Topline results from Pharming’s separate Phase II study in common variable immunodeficiency (CVID) are expected in November and will inform plans for a potential registrational study in the broader CVID population.